证券代码：000705 证券简称：浙江震元 公告编号：2025-013 浙江震元股份有限公司 2025 年度 日常关联交易预计的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、日常关联交易基本情况 （一）日常关联交易概述 公司在生产经营过程中与本公司关联方绍兴震元健康产业集团有限公司、浙 江省诸暨市医药药材有限公司、太极集团浙江东方制药有限公司以及绍兴市棒垒 球场建设运营有限公司等，发生药品及其他产品采购、药品及其他产品销售、房 产租赁等日常关联交易。2024 年度，公司关联方发生的关联交易金额为 1,102.62 万元。 以公司 2024 年及以往年度的关联交易为参考，对公司及子公司 2025 年度 将发生的日常关联交易做出预测。2025 年度，公司预计向关联方浙江省诸暨市 医药药材有限公司、太极集团浙江东方制药有限公司采购、销售商品总额为 580 万元，向关联方绍兴震元健康产业集团有限公司租赁、出租房产等 260 万元。 本次《关于 2025 年度日常关联交易预计的议案》已经公司 2025 年 4 月 27 日召开的十一届七次董事会审议通过，关联 ...

浙江震元股份有限公司 2024 年度内部控制自我评价报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 根据《企业内部控制基本规范》及其配套指引的规定和其他内部控制监管要 求（以下简称企业内部控制规范体系），结合本公司（以下简称公司）内部控制制 度和评价办法，在内部控制日常监督和专项监督的基础上，我们对公司 2024 年 12 月 31 日（内部控制评价报告基准日）的内部控制有效性进行了评价。 一、重要声明 按照企业内部控制规范体系的规定，建立健全和有效实施内部控制，评价其 有效性，并如实披露内部控制评价报告是公司董事会的责任。监事会对董事会建 立和实施内部控制进行监督。经理层负责组织领导企业内部控制的日常运行。公 司董事会、监事会及董事、监事、高级管理人员保证本报告内容不存在任何虚假 记载、误导性陈述或重大遗漏，并对报告内容的真实性、准确性和完整性承担个 别及连带法律责任。 证券代码：000705 证券简称：浙江震元 公告编号：2025-012 二、内部控制评价结论 根据公司财务报告内部控制重大缺陷的认定情况，于内部控制评价报告基准 日，不存在财务报告内部 ...

浙江震元股份有限公司董事会 2025 年 4 月 27 日 经核查独立董事冯坚、胡素华、汪宏伟、袁建伟的任职经历以及签署的相关 自查文件等内容，上述人员未在公司担任除独立董事以外的任何职务，也未在公 司主要股东公司担任任何职务，与公司以及主要股东之间不存在利害关系或其他 可能妨碍其进行独立客观判断的关系，不存在影响独立董事独立性的情况，符合 《上市公司独立董事管理办法》《深圳证券交易所上市公司自律监管指引第 1 号 ——主板上市公司规范运作》中对独立董事独立性的相关要求。 浙江震元股份有限公司董事会 关于独立董事独立性自查情况的专项报告 根据《上市公司独立董事管理办法》《深圳证券交易所股票上市规则》《深圳 证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运作》等要求， 浙江震元股份有限公司（以下简称"公司"）董事会，就公司在任独立董事冯坚、 胡素华、汪宏伟、袁建伟的独立性情况进行评估并出具如下专项意见： ...

浙江震元股份有限公司 2024 年度会计师事务所履职情况的评估报告 | 事务所名称 | 容诚会计师事务所(特殊普通合伙) | | | | --- | --- | --- | --- | | 成立日期 | 1988年8月 组织形式 | | 特殊普通合伙企业 | | 注册地址 | 北京市西城区阜成门外大街 22号 1幢 10层 1001-1至 | | 1001-26 | | 首席合伙人 | 刘维 2024年末合伙人数量 | | 212人 | | 2024 年末执业人 | 注册会计师 | | 1552人 | | 员数量 | 签署过证券服务业务审计报告的注册会计师 | | 781人 | | | 业务收入总额 287,224.60 | 万元 | | | 2023 年（经审 计） | 审计业务收入 274,873.42 | 万元 | | | 业务收入 | 证券业务收入 149,856.80万元 | | | | | 客户家数 394家 | | | | | 审计收费总额 48,840.19万元 在制造业（包括但不限于计算机、通信和其他 | | | | | 电子设备制造业、专用设备制造业、电气机械 和器材制造业、化学原料和化学 ...

Financial Performance - The company's revenue for Q1 2025 was ¥751,668,062.61, representing a decrease of 28.05% compared to ¥1,044,651,488.68 in the same period last year[8] - Net profit attributable to shareholders increased by 86.44% to ¥35,882,600.01 from ¥19,245,988.18 year-on-year[8] - The company reported a significant reduction in accounts payable from RMB 510,619,655.96 to RMB 323,960,756.68, a decrease of about 36.6%[22] - Total operating revenue for the current period is RMB 751,668,062.61, a decrease of 28.0% compared to RMB 1,044,651,488.68 in the same period last year[23] - Total operating costs decreased to RMB 730,914,225.65, down 28.4% from RMB 1,019,976,642.09 year-on-year[23] - Net profit for the current period is RMB 35,867,447.62, an increase of 77.0% compared to RMB 20,240,468.56 in the previous year[23] - Basic and diluted earnings per share increased to RMB 0.1074 from RMB 0.0576, representing an 86.5% increase[23] - Other comprehensive income after tax for the current period is RMB 4,513,320.00, compared to a loss of RMB 21,721,983.02 in the previous year[23] - The company reported a total comprehensive income of RMB 40,380,767.62, a significant improvement from a loss of RMB 1,481,514.46 in the same period last year[23] Cash Flow and Assets - The net cash flow from operating activities was negative at -¥16,740,662.01, a decline of 138.11% compared to ¥43,926,318.16 in the previous year[8] - Cash flow from operating activities showed a net outflow of RMB 16,740,662.01, compared to a net inflow of RMB 43,926,318.16 in the same period last year[24] - Cash and cash equivalents decreased from RMB 549,426,935.55 to RMB 503,331,890.71, a decline of approximately 8.4%[22] - Cash and cash equivalents at the end of the period amounted to RMB 498,576,036.67, compared to RMB 486,178,430.11 at the end of the previous year[24] - Investment activities resulted in a net cash outflow of RMB 190,181,627.49, compared to a net outflow of RMB 80,741,808.42 in the previous year[24] - Financing activities generated a net cash inflow of RMB 174,588,961.56, an increase from RMB 69,804,296.42 in the same period last year[24] - Total assets decreased by 15.78% to ¥2,879,386,418.21 from ¥3,418,794,511.15 at the end of the previous year[8] - Total current assets decreased from RMB 2,149,694,647.26 to RMB 1,466,501,063.70, a decline of approximately 31.6%[22] - Total liabilities decreased from RMB 1,457,032,752.65 to RMB 875,603,990.21, a decline of about 40%[22] - Total equity attributable to shareholders increased from RMB 1,960,598,883.36 to RMB 2,003,782,428.00, an increase of about 2.2%[22] Shareholder Information - The total number of common shareholders at the end of the reporting period is 32,139[16] - The largest shareholder, Shaoxing Zhenyuan Health Industry Group Co., Ltd., holds 24.93% of shares, totaling 83,300,474 shares[16] - The top 10 shareholders collectively hold a significant portion of the company's shares, with the largest shareholder holding nearly 25%[16] - The company received a total capital increase of 119.86 million RMB from China Resources Pharmaceutical Group Co., Ltd. on January 26, 2025[18] - After the capital increase, the company holds 49% equity in Zhenyuan Pharmaceutical, which will no longer be included in the consolidated financial statements[18] Investment and Equity Changes - The company's long-term equity investment increased by 37,059.34% to ¥87,133,675.78, primarily due to a change in ownership structure after the subsidiary Zhenyuan Pharmaceutical's capital increase[12] - The company reported an investment income of ¥26,610,884.29, a significant increase of 5,107.76% compared to ¥510,984.88 in the previous year, attributed to the disposal of the subsidiary Zhenyuan Pharmaceutical[13] - The company experienced a 47.71% decrease in accounts receivable, dropping to ¥362,581,375.51 from ¥693,387,618.76, mainly due to the capital increase of Zhenyuan Pharmaceutical[12] - The company’s inventory decreased by 29.40% to ¥506,402,964.86 from ¥717,234,287.22 year-on-year[12] - The company’s total liabilities decreased significantly, with short-term borrowings dropping to zero, a 100% decrease, due to the exclusion of Zhenyuan Pharmaceutical from the consolidated financial statements[12] Audit and Future Outlook - The first quarter report for 2025 has not been audited[20] - The company has not disclosed any changes in the shareholding structure due to securities lending activities[17] - The report indicates that there are no preferred shareholders or significant changes in preferred stock ownership[17] - The company has not provided any specific guidance or outlook for future performance in the conference call[19] - The report does not mention any new product developments or market expansion strategies[19]

Financial Performance - The company's operating revenue for 2024 was ¥3,740,688,470.19, a decrease of 8.91% compared to ¥4,106,371,595.40 in 2023[17]. - The net profit attributable to shareholders for 2024 was ¥34,729,260.48, down 57.46% from ¥81,642,566.28 in 2023[17]. - The basic earnings per share for 2024 was ¥0.10, a decline of 58.33% compared to ¥0.24 in 2023[18]. - The net cash flow from operating activities for 2024 was ¥76,095,427.47, a decrease of 16.21% from ¥90,819,928.90 in 2023[18]. - Total assets at the end of 2024 were ¥3,418,794,511.15, an increase of 16.32% from ¥2,939,079,216.37 at the end of 2023[18]. - The company's net assets attributable to shareholders at the end of 2024 were ¥1,960,598,883.36, a slight decrease of 0.78% from ¥1,975,931,610.49 at the end of 2023[18]. - The company reported a significant decline in quarterly net profit, with a loss of ¥8,839,681.30 in Q4 2024[22]. - The company recognized non-operating income of ¥7,626,006.51 in 2024, compared to ¥3,430,105.46 in 2023[24]. - The company achieved a total revenue of 118,105.65 million CNY, with 117,802.33 million CNY generated from stores within Shaoxing city[46]. - The company achieved a total revenue of 3.741 billion yuan in 2024, a decrease of 8.91% compared to the previous year[59]. - The net profit attributable to shareholders was 34.73 million yuan, down 57.46% year-on-year[59]. Dividend and Shareholder Information - The company plans to distribute a cash dividend of 0.6 RMB per 10 shares to all shareholders, based on a total of 334,123,286 shares[4]. - The total distributable profit for the parent company was 425,630,467.55 yuan, with the cash dividend representing 100% of the profit distribution[154]. - The annual shareholders meeting had an investor participation rate of 38.47% on April 12, 2024[124]. - The first extraordinary shareholders meeting had a participation rate of 34.76% on May 20, 2024[124]. - The second extraordinary shareholders meeting had a participation rate of 27.56% on September 4, 2024[124]. - The third extraordinary shareholders meeting had a participation rate of 27.55% on December 4, 2024[124]. Operational Strategy and Market Position - The company is focused on expanding its market presence through direct-to-patient (DTP) services and online-to-offline (O2O) business models[9]. - The company has undergone multiple changes in its business scope since its listing, with the latest update on August 10, 2023, including drug wholesale, food sales, and third-class medical device operations[15]. - The company has diversified its sales channels, now including e-commerce and various retail formats for food and healthcare products[15]. - The company is positioned to leverage its diverse product portfolio to capture growth opportunities in the healthcare and wellness sectors[15]. - The company is actively involved in the national drug procurement program, which has included 62 types of drugs in 2024, contributing to cost reduction for patients[38]. - The company is currently expanding its market presence through acquisitions, including 100% ownership of Shaoxing Tongyuan Health Management Co., Ltd.[102]. - The company plans to enhance its market influence through innovative retail strategies and integration of its wholesale business, while focusing on quality control in traditional Chinese medicine[111]. Research and Development - The company emphasizes the importance of innovation in drug research and development, particularly in the context of generic drug consistency evaluation risks[4]. - The company is advancing multiple R&D projects aimed at enhancing product quality and reducing costs, with a focus on fermentation technology[81]. - R&D investment increased by 20.53% to ¥55,633,361.80 in 2024, compared to ¥46,157,291.31 in 2023, with R&D expenditure accounting for 1.49% of operating revenue[82]. - The number of R&D personnel rose to 117 in 2024, a 2.63% increase from 114 in 2023, with a notable 40% increase in master's degree holders[82]. - The company launched over 50 self-operated products during the reporting period, expanding its proprietary brand product range[62]. - The company’s subsidiary, Zhejiang Zhenyuan Pharmaceutical, reported a net profit of ¥2,704.95, contributing significantly to the overall profitability of the company[101]. Governance and Compliance - The report highlights the company's commitment to transparency and accuracy in financial reporting, with all board members present for the meeting[4]. - The company has a robust governance structure in place, ensuring accountability and compliance with regulatory requirements[4]. - The company is focused on enhancing its governance structure with new appointments aimed at improving operational efficiency[128]. - The company is committed to maintaining a robust management team to navigate future challenges and opportunities[128]. - The internal control self-assessment report was disclosed on April 29, 2025, indicating that 100% of the assets and revenue of the evaluated units were included in the consolidated financial statements[159]. - The internal control audit report issued by the accounting firm confirmed the effectiveness of the internal control system without any reservations[160]. Environmental Responsibility - The company holds a valid pollution discharge permit, effective until December 31, 2025, demonstrating compliance with environmental regulations[163]. - The total amount of hazardous waste discharged by the company was 2,336.93 tons, with no instances of exceeding discharge limits reported[164]. - Zhenyuan Pharmaceutical has implemented a standardized management system for hazardous waste, including classified collection and disposal, with a fully cemented hazardous waste storage area[166]. - The company has made significant investments in environmental governance, ensuring the normal operation of pollution control facilities and timely payment of environmental protection taxes[169]. - Zhenyuan Pharmaceutical actively engages in community health services, conducting over 120 events related to medication safety and health education[169]. Challenges and Risks - The management discussed various operational risks, including market competition and raw material price fluctuations, which could impact future performance[4]. - The company has experienced uncertainty regarding its ability to continue as a going concern, as indicated by recent audit reports[18]. - The pharmaceutical industry is expected to face intensified competition and regulatory pressures, with a focus on innovation and digitalization, as well as the growth of traditional Chinese medicine[104]. - The average profit margin in the pharmaceutical industry is under pressure due to centralized procurement policies, necessitating resource integration for improved operational efficiency[105]. - The company is facing risks from industry policy changes, market competition, and raw material price fluctuations, necessitating strategic adjustments and enhanced research efforts[114].

证券代码：000705 证券简称：浙江震元 公告编号：2025-019 浙江震元股份有限公司 关于延长公司 2024 年度向特定对象发行股票 股东大会决议有效期及相关授权有效期的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 浙江震元股份有限公司（以下简称"公司"）于2025年4月27日召开十一届 七次董事会，审议通过了《关于延长公司2024年度向特定对象发行股票股东大会 决议有效期的议案》《关于提请股东大会延长授权董事会办理公司2024年度向特 定对象发行股票相关事宜有效期的议案》。上述议案尚需提交公司2024年度股东 大会审议。现将具体情况公告如下： 一、关于延长向特定对象发行股票发行方案决议有效期及相关授权有效期 的情况说明 2024年5月20日，公司2024年第一次临时股东大会审议通过了《关于公司向 特定对象发行股票方案的议案》、《关于提请股东大会授权董事会办理本次向特 定对象发行股票相关事宜的议案》等相关议案，根据上述股东大会决议，公司本 次向特定对象发行股票的股东大会决议有效期和授权董事会全权办理本次向特 定对象发行股票相关事宜的有效期为20 ...

证券代码：000705 证券简称：浙江震元 公告编号：2025-020 浙江震元股份有限公司 关于召开 2024 年度股东大会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 3. 会议召开的合法、合规性：本次股东大会会议召开符合《公司法》、《公 司章程》的相关规定。 4.会议召开日期、时间：2025 年 5 月 19 日（星期一）下午三时召开现场会议 网络投票时间：2025 年 5 月 19 日 其中：通过深圳证券交易所交易系统进行网络投票的时间为一天，具体时间 为：2025 年 5 月 19 日 9:15-9:25、9:30-11:30、13:00-15:00；通过深圳证券交 易所互联网投票系统投票的具体时间为：2025 年 5 月 19 日 9:15-15:00。 5.会议的召开方式：本次股东大会采用现场表决与网络投票相结合的方式召 开。 6.本次股东大会的股权登记日：2025 年 5 月 12 日（星期一）。 7.出席对象： （1）在股权登记日持有公司股份的普通股股东或其代理人； 截至 2025 年 5 月 12 日（星期一）下午收市时在中国结算 ...

浙江震元股份有限公司十一届七次监事会决议公告 证券代码：000705 证券简称：浙江震元 公告编号：2025-021 浙江震元股份有限公司十一届七次监事会决议公告 本公司及监事会全体成员保证公告内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 一、监事会会议召开情况 浙江震元股份有限公司十一届七次监事会会议通知于 2025 年 4 月 17 日以书 面、通讯等形式发出，2025 年 4 月 27 日以通讯形式召开。本次会议应出具表决意 见监事 4 人，实际出具表决意见监事 4 人，会议的召开符合有关法律、行政法规、 部门规章、规范性文件和公司章程的规定。 3、审议通过《2024 年度利润分配预案》 表决结果：4 票同意，0 票反对，0 票弃权。具体内容详见同日披露的《浙江 震元股份有限公司关于 2024 年度利润分配预案的公告》（公告编号：2025-011）， 本议案需提交公司 2024 年度股东大会审议。 4、审议通过《2024 年度内部控制自我评价报告》 表决结果：4 票同意，0 票反对，0 票弃权。监事会认为：公司根据中国证监 会、深圳证券交易所的有关规定，遵循内部控制的基本原则，结合公司实 ...

股票代码：000705 股票简称：浙江震元 公告编号：2025-009 浙江震元股份有限公司 关于为子公司震元生物提供担保的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、担保情况概述 （一）担保基本情况 2025 年 4 月 24 日，浙江震元股份有限公司（以下简称"公司"）与绍兴银行 股份有限公司（以下简称"绍兴银行"）签署《最高额保证合同》（合同编号： 0900202504230200），为子公司浙江震元生物科技有限公司（以下简称"震元生 物"）2025 年 4 月 24 日至 2026 年 4 月 24 日期间内，向绍兴银行取得的人民币 1,000 万元整（壹仟万元整）贷款提供连带责任保证。 （二）本次担保事项履行的审议程序 公司召开第十一届董事会 2025 年第一次临时会议审议通过《关于为子公司震 元生物增加担保额度的议案》，同意公司为震元生物提供信用担保，12 个月内累 计总额不超过人民币 10,000 万元。担保期限自董事会批准同意日起一年内，担保 额度在授权期限内可循环使用。 二、被担保人基本情况 公司名称：浙江震元生物科技有限公 ...